75 percent of patients now enrolled in Diamyd Medical’s European Phase II trial
Three quarters, 80 out of 106 patients, are included in the European Phase II trial DIAGNODE-2, where the diabetes vaccine Diamyd® is administered directly into the lymph node. In January, a new clinic is expected to open for recruitment in Rotterdam, the Netherlands.“The interest in DIAGNODE-2 continues to be high,” says Ulf Hannelius, CEO of Diamyd Medical. “The goal is a fully recruited trial in the first quarter of 2019. I would like to wish everyone Happy Holidays and best wishes for the New Year.” About type 1 diabetesType 1 diabetes is an autoimmune disease where the beta cells,
